FindTrial
Sign In

Canagliflozin (JNJ-28431754) 300 mg

DRUG2 trials

Sponsors

Janssen Research & Development, LLC, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions

Cardiovascular DiseasesDiabetes Mellitus, Type 2HealthyRisk Factors

Phase 1

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers
CompletedNCT01748526
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy
Start: 2008-08-31End: 2008-09-30Updated: 2016-07-19

Phase 3

CANVAS - CANagliflozin cardioVascular Assessment Study
CompletedNCT01032629
Janssen Research & Development, LLCCardiovascular Diseases, Diabetes Mellitus, Type 2, Risk Factors
Start: 2009-12-09End: 2017-02-22Updated: 2018-12-07

Related Papers

Impact of canagliflozin on heart stress and outcomes: Pooled insights from <scp>CREDENCE</scp> and <scp>CANVAS</scp>
European Journal of Heart Failure2025-07-211 citations
A validated multivariable machine learning model to predict cardio-kidney risk in diabetic kidney disease
Cardiovascular Diabetology2025-05-151 citations
Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females
Blood Advances2025-04-167 citations
The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the <scp>CANVAS</scp> and <scp>CREDENCE</scp> Trials
Journal of the American Geriatrics Society2025-03-195 citations
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant‐level pooled analysis of the <scp>CANVAS</scp> and <scp>CREDENCE</scp> trials
European Journal of Heart Failure2025-01-233 citations
Effects of Canagliflozin on Total Heart Failure Events Across the Kidney Function Spectrum: Participant-Level Pooled Analysis from the CANVAS Program and CREDENCE Trial
European Journal of Heart Failure2024-06-264 citations
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial
Journal of the American Heart Association2024-01-194 citations
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
Journal of the American Heart Association2023-06-226 citations
Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS
The Journal of Clinical Endocrinology & Metabolism2023-05-0733 citations
Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE.
2023-04-297 citations
Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial.
2022-11-289 citations
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
2022-11-017 citations
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
2022-02-0136 citations
Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease
Clinical Journal of the American Society of Nephrology2021-12-0746 citations
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials.
2021-06-1525 citations
Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial
Cardiovascular Research2021-04-0619 citations
Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
2020-11-0169 citations
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
2020-09-2151 citations
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program
Journal of the American Society of Nephrology2020-07-2121 citations
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.
2019-10-29112 citations

20 more papers not shown